Compare CTM & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | PMVP |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 81.3M |
| IPO Year | 2022 | 2020 |
| Metric | CTM | PMVP |
|---|---|---|
| Price | $0.54 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 326.9K | ★ 610.4K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,866,001.00 | N/A |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.48 | $1.02 |
| 52 Week High | $1.36 | $1.91 |
| Indicator | CTM | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 42.53 |
| Support Level | $0.48 | $1.24 |
| Resistance Level | $0.66 | $1.31 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 25.73 | 10.66 |
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.